Focus: Corcept Therapeutics is a California-based specialty biotech focused on small-molecule treatments for rare endocrine and oncology indications. The company operates at mid-cap scale (201–500 employees) with a concentrated commercial footprint.
Profile data last refreshed 14h ago · AI intelligence enriched 2w ago
Contracting — net -21 jobs in 30d
23 added, 44 removed. Active reduction in progress.
A stable, specialist play suited to clinical specialists seeking rare-disease expertise and Phase 3 catalysts, but with material revenue-concentration and pipeline-depth risks that require tolerance for restructuring.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver and only approved indication; generates 100% of company revenue through 2038 patent exclusivity.
Help build intelligence for Corcept Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Corcept Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Generic entry post-LOE on branded mifepristone; limited commercial upside, primarily defensive positioning.
Non-core indication; subject to regulatory and public-policy risk; approaching loss of exclusivity.
Second generic ANDA filing; further commoditization of mifepristone outside KORLYM brand; minimal value.
Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT) The Globe and Mail
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics - The Globe and Mail
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics The Globe and Mail
Corcept Therapeutics Incorporat (CORT) Stock forecasts - Yahoo Finance Australia
Corcept Therapeutics Incorporat (CORT) Stock forecasts Yahoo Finance Australia
What Corcept Therapeutics Holders Saw Early - Simply Wall Street
What Corcept Therapeutics Holders Saw Early Simply Wall Street
A director's trust sells 10,000 shares under a trading plan at Corcept Therapeutics (CORT). - Stock Titan
A director's trust sells 10,000 shares under a trading plan at Corcept Therapeutics (CORT). Stock Titan
Corcept Therapeutics Incorporat (CORT) Stock forecasts - Yahoo Finance UK
Corcept Therapeutics Incorporat (CORT) Stock forecasts Yahoo Finance UK
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo